1. Jim Joyce
Chairman, CEO
January 9, 2012
My presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether
and when our products are successfully developed and introduced, market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and
other product offerings, regulatory delays, manufacturing delays, and other risks detailed in our sec filings accessible at www. Sec.gov.

2. We create medical devices to address unmet
medical needs in cancer, infectious disease,
and other life-threatening conditions

3. The transition from development-stage
to revenue-stage organization

5. Adaptive Dialysis-like Affinity Platform Technology

6. The intersection of medical device
technology and affinity drug mechanisms
Mabs
Dialysis
ADAPT Lectins
Plasmapheresis Aptamers

7. Target binding is
Effective target separation
highly selective
No target discrimination Toxicity Limits Dosing

8. High specificity
Indiscriminate ADAPT Toxicity
Effective separation

9. The Hemopurifier®
An Aethlon ADAPT™ Therapy

10. Aethlon ADAPT™ therapies seamlessly integrate
into the infrastructure of dialysis and CRRT
machines located in hospitals in clinics worldwide

11. Aethlon ADAPT™ therapies provide access
to the entire circulatory system
• Rapid real-time access to single or
multiple therapeutic targets in as
little as 15 minutes
• Adjunct to improve SOC therapy
benefit without adding drug toxicity
or interaction risks
• Able to address targets beyond
the reach of drugs

12. The future is home based therapy

18. The Aethlon Hemopurifier®
• The lead Aethlon ADAPT™ treatment
candidate
• Broad-spectrum capture of viral
pathogens and immunosuppressive
exosomes underlying cancer and
infectious disease
• Compelling HCV & HIV/AIDS treatment
outcomes in ESRD patient population

22. • The Drug Industry
• Provides medical device pathway for affinity drug agents
• $5 million vs. $500 million
• Repurposes approved, clinical stage & previous clinical dropouts
• Military & Government Health Agencies
• Seeking innovative therapeutic solutions

26. Viral Load Reduction by Drugs Alone
$!!"#
,!"#
+!"#
!"#$%&'(")*+"+%,'("-.'/"
*!"#
)!"#
(!"#
'!"#
&!"#
%!"#
$!"#
!"#
!# $# %# &# '# (# )# *#
0%12"3/'456"

27. Viral Load Reduction by Hemopurifier Alone
$!!"#
,!"#
+!"#
!"#$%&'(")*+"+%,'("-.'/"
*!"#
)!"#
(!"#
'!"#
&!"#
%!"#
$!"#
!"#
!# $# %# &# '# (# )# *#
0%12"3/'456"

28. Viral Load Reduction by Drugs and
Hemopurifier in Combination
$!!"#
,!"# -.#/0123#45#'607/89# :0123#8;.<=#>0=/?@A=/#
+!"#
:0123#B#45#'60#>0=/?@A=/# :0123#8;.<=#.C3#
!"#$%&'(")*+"+%,'("-.'/"
*!"#
)!"#
(!"#
'!"#
&!"#
%!"#
$!"#
!"#
!# $# %# &# '# (# )# *#
0%12"3/'456"

29. Comparasion to RVR Achievement
7000000
6000000
5000000
Viral Load ul/ml
4000000
SOC Alone
3000000 SOC + Hemopurifier®
2000000
1000000
0
Day 1 Pre 3 post 7 post D-10 D-14 D-17 D-21 D-24 30 post
Day

32. Contact
Jim Joyce
Chairman, CEO
8910 University Center Lane
San Diego, California 92122
858.459.7800 x301
jj@aethlonmedical.com